Gene Editing's Double Edge: Power, Patents, and the Future of Biotech Accountability
"Explore the ethical battleground of foundational technologies and their potential to reshape society. Who decides how these tools are used, and what's at stake?"
The rapid advancement of biotechnology offers unprecedented potential to reshape our world, from eradicating diseases to engineering entire ecosystems. At the heart of this revolution lie "foundational technologies" like CRISPR-Cas9, powerful tools that serve as building blocks for future innovations. But with great power comes great responsibility, and these technologies raise profound questions about who controls their use and for what purposes.
Intellectual property rights, particularly patents, play a pivotal role in shaping the trajectory of these technologies. While patents are intended to incentivize innovation, they can also create monopolies that restrict access and dictate the direction of research. This is especially concerning with foundational technologies, where control over a single patent can have far-reaching consequences for society.
This article delves into the complex interplay between foundational technologies, patent law, and social accountability. Inspired by recent discussions on the ethical implications of gene editing and related biotechnologies, we explore how patent holders wield "configuration power" – the ability to influence the very architecture of socio-technical systems – and what this means for the future of innovation.
A Rapidly Expanding Market
The global gene editing market was valued at USD 10.31 billion in 2025 and is projected to grow from USD 10.98 billion in 2026 to USD 35.02 billion by 2034, exhibiting a compound annual growth rate of 15.60%. CRISPR, the dominant gene editing technique, is based on a simplified version of the bacterial CRISPR-Cas9 antiviral defense system and can be applied to organisms ranging from plants and animals to humans. The technology offers the potential to treat genetic diseases by correcting or altering faulty genes responsible for those conditions.
Promising Methods, Persistent Roadblocks
Genome editing is increasingly recognized as an important technology for achieving stable therapeutic effects in gene correction, with hematopoietic cells representing a key target for treating hereditary diseases, infections, and cancer. However, scientists have identified specific genes that actively block CRISPR editing; inhibiting the top two such genes increased editing efficiency by more than three and a half times in patient-derived retinal cells carrying the genetic eye disease Leber congenital amaurosis. The NIH Somatic Cell Genome Editing Consortium is working to develop and standardize platform technologies so that scientists can plug new guide RNAs into a system to target different genetic locations in various cells. Despite these advances, genome editing and multi-omics approaches can introduce conceptual flaws that distort understanding of gene function and biological discovery.
From DNA Manipulation to CRISPR
Genetic engineering is defined as the artificial manipulation, modification, and recombination of DNA or other nucleic acid molecules to modify an organism, a field rooted in recombinant DNA technology. CRISPR gene editing, the most prominent modern technique, modifies the genomes of living organisms using a system derived from bacterial antiviral defenses. The broader trajectory from early recombinant DNA methods to CRISPR represents a fundamental shift in humanity's capacity to alter biological organisms at the molecular level.
The Configuration Power of Patents
Traditionally, intellectual property scholarship has focused on stimulating innovation, often sidelining concerns about social justice and equitable access. However, groundbreaking technologies challenge this narrow view, highlighting how patents on foundational innovations can exacerbate inequalities. Patents can lead to higher prices, narrow research agendas, inhibit the development of alternatives, and create uncertainty that discourages investment. But the issue goes beyond mere access and price; it's about the power to shape the very norms and values embedded in these technologies.
- Increased Costs: Patents can lead to monopolistic pricing, making essential technologies unaffordable.
- Narrowed Research: Focus shifts to patented technologies, potentially neglecting alternative solutions.
- Inhibited Innovation: Uncertainty around patent access discourages investment in related research.
- Social Impact: Patent holders influence the normative choices embedded in technologies, impacting society.
Off-Target Detection and New Applications
CRISPR gene editing promises new therapies but raises concerns about unintended changes, prompting the development of UNCOVERseq, an in-cell method that sensitively detects rare off-target edits and benchmarks performance across different editors. Researchers are also exploring CRISPR applications beyond disease treatment, including editing of allergens such as the cat allergen Fel d 1, though the advantages and limitations of this approach compared to existing treatment options remain under discussion. Meanwhile, scientists have captured a "jumping gene" mid-leap between species, advancing understanding of transposable elements and their role in genome evolution.
Ethical Concerns and Distributional Critiques
Critics of using gene editing to boost food production argue that there is already sufficient food in the world and that the core problem is one of distribution rather than supply, a point acknowledged by agricultural researchers such as Dr. Hans Braun of CIMMYT's global wheat programme. Beyond food security, gene editing intersects with cancer immunotherapy in ways that raise complex questions about therapeutic scope and risk. The broader political dimension has also been framed as a form of "political gene-editing," in which critical and emerging technologies perform a constitutive reengineering of state structures and Westphalian norms of sovereignty.
Alternatives, Regulation, and Immunological Parallels
While germline editing remains highly controversial, alternatives such as preimplantation genetic testing and gene therapy exist, though the lack of international regulation highlights the need for careful consideration of the technology's ethical implications. Immunological research offers a comparative lens: studies of macrophage polarization have identified distinct gene signatures in classically activated M1 versus alternatively activated M2 macrophages, with 28 genes found to be differentially regulated between the two states. These immunological gene signature comparisons illustrate how gene expression analysis tools developed alongside editing technologies can illuminate fundamental biological questions.
The Path Forward: Reimagining Accountability
Patents allocate more than just economic benefits; they allocate leverage in negotiations that shape our technological and social orders. Configuration power enabled Myriad to impose normative judgments about management of uncertainty, eligibility for testing, and responsibility for post-test counseling, as well as to make technical choices and capture proprietary control of invaluable data. The question is not whether patents are inherently good or bad, but how we can ensure that they are used in a way that promotes both innovation and social well-being. This requires a broader conversation about the role of foundational technologies in shaping society, and the need for greater democratic choice and accountability in the innovation process.
Data Challenges and Expert Risk Assessment
Experts have identified significant data challenges relevant to the development and approval of new genome-edited crop traits, including mechanisms for managing and protecting proprietary data throughout the regulatory pipeline. A comparative analysis of regulatory frameworks across selected countries and the EU reveals divergent approaches to governing plant biotechnology, complicating international commercialization. Expert opinion surveys also reveal split risk preferences when comparing alternative nucleic acid-based technologies, with regional and expertise-based differences shaping views on which editing approaches deserve prioritization for agricultural impact.
Base Editing, Prime Editing, and Market Projections
Key trends in the CRISPR genomic cure market include the rise of base editing and prime editing technologies, which offer more precise gene editing capabilities than earlier CRISPR-Cas9 approaches. The global gene editing market is projected to reach $19 billion by 2030, though corporations are racing to patent genetic sequences and frame DNA as intellectual property, raising questions about who decides what genetic traits are desirable. While gene-editing technologies could eventually reduce the likelihood of common human diseases, experts caution that the technology is currently unproven and unsafe for widespread clinical application.
Therapeutic Breadth and Corporate Stakes
A genome-editing technology described in Cell Research in 2019 demonstrated potential applicability across a broad range of gene mutation conditions, including Huntington's disease and the rare premature aging syndrome progeria. On the commercial side, Eli Lilly's $1.12 billion gene-editing deal has sparked investor turbulence, illustrating the financial volatility surrounding biotech partnerships even as the therapeutic promise expands. These developments underscore the tension between the expanding technical capability of gene editing tools and the systemic challenges of bringing them safely and equitably to market.
From Lab to Patient: Promise and Precaution
The case of Chinese scientist He Jiankui, who created the world's first gene-edited babies, remains a defining cautionary tale about the ethical boundaries of human genetic modification. On the therapeutic front, CRISPR has helped a desperately ill baby thrive using a base editing technique that flips a mutated DNA letter to its correct form rather than cutting the DNA strand, though gene-editing therapies for the nervous system may need at least another round of studies before they are safe enough to enter human trials. Prime editing has shown promise in correcting the most frequent mutations responsible for phenylketonuria, validating a strategy that could eventually benefit a large proportion of individuals with this inherited metabolic disorder.